Table 3 DCs and antitumor therapy
From: Deciphering tumor-infiltrating dendritic cells in the single-cell era
Treatment | Cancer type | Findings |
|---|---|---|
Anti-PD-L1 therapy | Breast cancer | Increased cDC1, LAMP3+ DC, and pDC levels are associated with therapeutic response [35] |
Chemotherapy | Gastric cancer | Number of DCs decreases around tumors after two cycles of chemotherapy [61] |
Neoadjuvant immunochemotherapy | NSCLC | Significantly higher expression of LAMP3 after neoadjuvant immunochemotherapy [44] |
Neoadjuvant PD-1 blockade combined with chemotherapy | NSCLC | Increased proportion of cDC1s and cDC2s in responding patients and an accompanying increase in antigen presentation characteristics [45] |
Neoadjuvant chemotherapy | Esophageal adenocarcinoma | cDC suppression in the TME was corrected, and pDCs were significantly reduced [95] |
Neoadjuvant chemoradiotherapy | Esophageal squamous cell carcinoma | Decrease in cDC1s and LAMP3+ cDCs [51] |
Neoadjuvant anti-PD1 therapy | Recurrent glioblastoma | Specific chemokine receptor–ligand interaction between XCR1 and XCL1/2, suggesting the recruitment of cDC1 by intratumoral cytotoxic T cells [94] |
Immunotherapy | Gastric cancer | Proportion of moDC clusters decreases compared to chemotherapy, antigen presentation and pro-angiogenic capacity downregulated, and an anti-inflammatory phenotype in response to immunotherapy [63] |
Radiochemotherapy | Cervical cancer | Decreased cDC1 relative proportion, increased gene expressions associated with leukocyte migration and activation, and enrichment of antigen processing and presentation [53] |